AdAlta Ltd
1AD
Company Profile
Business description
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. Its principal activity is the development of next-generation cellular immunotherapies for the treatment of solid cancers, together with thecommercialisation of protein therapeutics previously discovered using the Company's proprietary i-body platform.
Contact
117 Camberwell Road, Hawthorn East
Level 1, Suite 1.01
CamberwellVIC3123
AUST: +61 394795159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
2
Stocks News & Analysis
stocks
Reassuring organic growth for undervalued ASX share
Efficiency gains are starting to make their mark.
stocks
Big IPOs are enticing but are they good investments?
Historically, buzzy debuts have been painful for buyers.
stocks
This defensive ASX listed REIT offers a 5% yield
Solid outlook underpinned by rent uplifts and development pipeline.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,692.80 | 143.80 | -1.63% |
| CAC 40 | 7,927.75 | 152.99 | -1.89% |
| DAX 40 | 24,802.78 | 661.03 | -2.60% |
| Dow JONES (US) | 48,147.33 | 949.73 | -1.93% |
| FTSE 100 | 10,346.34 | 106.34 | -1.02% |
| HKSE | 22,410.80 | 430.82 | -1.89% |
| NASDAQ | 22,617.73 | 1,261.47 | -5.28% |
| Nikkei 225 | 56,436.65 | 3,007.56 | -5.06% |
| NZX 50 Index | 14,107.41 | 139.84 | -0.98% |
| S&P 500 | 6,910.39 | 265.44 | -3.70% |
| S&P/ASX 200 | 8,592.60 | 137.80 | -1.58% |
| SSE Composite Index | 3,533.79 | 43.82 | -1.22% |